SCHEMBL6551624

SCHEMBL6551624

BrCCCCc1ccccn1

nearest known ligand 0.63

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
HRH1 P35367 2/20 0.63
CYP1A2 P05177 4/20 0.54
SMN1; SMN2 Q16637 2/20 0.54
CYP2C19 P33261 2/20 0.54
NAAA Q02083 1/20 0.53
HRH3 Q9Y5N1 3/20 0.50
HRH4 Q9H3N8 2/20 0.49
ALDH1A1 P00352 2/20 0.48
LMNA P02545 1/20 0.48
TAAR1 Q96RJ0 1/20 0.48
ALOX15 P16050 1/20 0.48
MAPT P10636 1/20 0.48
LIN28A Q9H9Z2 1/20 0.48
TDP1 Q9NUW8 1/20 0.48
CYP2D6 P10635 1/20 0.46
HSD17B10 Q99714 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28136022 0.98 HRH1 (0.67) HRH1CYP1A2SMN1; SMN2CYP2C19NAAA
SCHEMBL29031284 0.98 HRH1 (0.67) HRH1CYP1A2SMN1; SMN2CYP2C19NAAA
SCHEMBL28669182 0.98 HRH1 (0.67) HRH1CYP1A2SMN1; SMN2CYP2C19NAAA
SCHEMBL29263622 0.98 HRH1 (0.67) HRH1CYP1A2SMN1; SMN2CYP2C19NAAA
SCHEMBL29145044 0.98 HRH1 (0.67) HRH1CYP1A2SMN1; SMN2CYP2C19NAAA
SCHEMBL9670413 0.98 HRH1 (0.67) HRH1CYP1A2SMN1; SMN2CYP2C19NAAA
Bromide SCHEMBL10378020 0.98 HRH1 (0.61) HRH1CYP1A2SMN1; SMN2CYP2C19NAAA
SCHEMBL28347622 0.98 HRH1 (0.67) HRH1CYP1A2SMN1; SMN2CYP2C19NAAA
SCHEMBL7007425 0.98 HRH1 (0.67) HRH1CYP1A2SMN1; SMN2CYP2C19NAAA
SCHEMBL27915750 0.98 HRH1 (0.67) HRH1CYP1A2SMN1; SMN2CYP2C19NAAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2576510-A1 PIPERIDINONE DERIVATIVES AS MDM2 INHIBITORS FOR THE TREATMENT OF CANCER Amgen Inc. (US) 2013-04-10 EP disclosed
WO-2011153509-A1 PIPERIDINONE DERIVATIVES AS MDM2 INHIBITORS FOR THE TREATMENT OF CANCER AMGEN INC. (US) 2011-12-08 WO disclosed
EP-1044991-B1 Process of preparing curable compositions and compositions therefrom ROHM & HAAS (US) 2004-02-11 EP disclosed
US-6645562-B2 Drying a coating of a liquid addition oligomer having pendant functional groups; modifying by curing and crosslinking with an unsaturated compound having a reactive group using a free radical catalyst; films, adhesives, coatings, paints and inks GREENBLATT GARY DAVID (US) 2003-11-11 US disclosed
US-20030069363-A1 Method of preparing a curable coating and curing thereof GREENBLATT GARY DAVID (US) 2003-04-10 US disclosed
US-20020137857-A1 Forming an oligomer containing reactive functional groups,and reacting a modifier that also contains reactive function groups with the oligomer ROHM AND HAAS COMPANY 2002-09-26 US disclosed
US-6433098-B1 CROSSLINKING; PHOTOPOLYMERIZATION ROHM AND HAAS COMPANY 2002-08-13 US disclosed
EP-1044991-A1 Process of preparing curable compositions and compositions therefrom ROHM AND HAAS COMPANY (US) 2000-10-18 EP disclosed
CN-1270186-A Method for preparing curable composition and composition therefrom ROHM & HAAS (US) 2000-10-18 CN disclosed
CN-1214701-A Ion Exchange Polymers for Anion Separation UNIV CALIFORNIA (US) 1999-04-21 CN disclosed
US-4636563-A Antipsychotic γ-carbolines AMERICAN HOME PRODUCTS CORPORATION (US) 1987-01-13 US disclosed